Personalis, Inc. (NASDAQ: PSNL) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Personalis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.80, Personalis, Inc. trades at 19.9x sales and 7.5x book value. Over the last twelve months it generated about $81M of revenue and a net loss of $127M. It runs a gross margin of 16.7%, an operating margin of -156.7% and a net margin of -147.7%. It shows return on equity of -49.5%, return on invested capital of -50.6% and a free cash flow yield of -6.7%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 4.53. Over the past 52 weeks the share price ranged from $4.96 to $18.89, with a beta of 2.36.
Personalis, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 8 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Personalis, Inc. (PSNL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.05% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.2% / 30% · Interest income / Revenue 6.88% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.05% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.2% / 33% · Receivables / Mkt Cap (36m) 1.06% / 49% · Interest income / Revenue 6.88% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.05% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.2% / 33.33% · Receivables / Mkt Cap (24m) 1.06% / 33.33% · Interest income / Revenue 6.88% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 5.29% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.4% / 33.33% · Receivables / Avg Assets (4Q) 4.94% / 33.33% · Interest income / Revenue 6.88% / 5% | Fail |
| FTSE | Debt / Total Assets 0.31% / 33.33% · (Cash+ST Inv) / Total Assets 65.4% / 33.33% · (Cash+Recv) / Total Assets 71.5% / 33.33% · Interest income / Revenue 6.88% / 5% | Fail |
No. As of September 2026, Personalis, Inc. (PSNL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Personalis, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 6.88% of each dividend: Personalis, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.